May 5, 2023
On April 30th, the Generics and Biosimilar Initiative (GaBI) published a meeting report on a 2-hour webinar entitled “Non-Medical Switching of Biologicals and Biosimilars: Canada, Europe, and the US”, hosted July 20th, 2022 by ASBM and GaBI. During the webinar, academic clinicians, patient advocates, policymakers and regulatory experts from Canada and the US shared their experience and […]
April 25, 2023
By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. Under this plan – authorized by the Inflation Reduction Act (IRA) signed in to law last year – Medicare will “negotiate” (set) maximum […]
April 11, 2023
On March 5th-6th, ASBM Chairman Ralph McKibbin, MD, FACP, FACG, AGAF participated in the 33rd annual Digestive Disease National Coalition public policy forum in Washington, DC March 5th and 6th. The advocacy conference brought together patient advocates, health care providers, and industry representatives from the major national voluntary and professional societies concerned with digestive diseases. […]
February 2, 2023
On January 31st, ASBM’s Immediate Past Chair Madelaine Feldman, MD, FACR and Executive Director Michael Reilly participated in the 2023 Treatment Choice Summit, held in Washington, DC. Dr. Feldman moderated the first panel discussion, Patient and Provider Perspectives on the Impact of Treatment Choice. The purpose of the discussion was to identify barriers to treatment choice and […]
January 30, 2023
In December, the Ontario government announced that it would follow other Canadian provinces including British Columbia, Alberta, Quebec and require mandatory switching to biosimilars. a mandatory switching in 2020, but implementation was delayed due to the COVID-19 pandemic. A nine-month transition period will begin March 31st. From the government’s announcement: Ontarians receiving coverage under the ODB […]
January 10, 2023
The Ohio State College of Pharmacy has provided ASBM with access codes for our Members who wish to view the first four modules of the ASBM/OSU College of Pharmacy Biosimilars Course at no charge: Biosimilars Module 1: Introduction to Biologics and Biosimilars (Prof. Philip Schneider, MS FASHP FFIP) Biosimilars Module 2: Substitution and Interchangeability (Prof. Philip Schneider, MS FASHP […]
January 10, 2023
In December, ASBM recorded the seventh and final module in its biosimilar Continuing Education (CE) Course on Biosimilars, presented with the Ohio State University College of Pharmacy. The latest module is entitled “PBMs and Payer Practices” and is presented by ASBM’s Immediate Past Chair Madelaine Feldman, MD, FACR. In this module Dr. Feldman explains unique […]
December 20, 2022
In December, the Generics and Biosimilar Initiative (GaBI) published a whitepaper entitled “US prescribers’ attitudes and perceptions about biosimilars”, based on the findings from ASBM’s survey of 401 U.S. physicians fielded in late 2021. The paper was authored by ASBM’s Chairman Ralph McKibbin, MD, FACP, FACG, AGAF; and Executive Director Michael S. Reilly, Esq. The survey examines […]
December 1, 2022
The Generics and Biosimilars Initiative (GaBI) has published a report on the first of two webinars the organization recently co-hosted with ASBM. The report summarizes the presentations from the June 29th webinar which examined “Key Factors for Successful Biosimilar Uptake in Europe, Canada and the US”. View the webinar below: The report also addresses audience questions that were unable to be […]
November 20, 2022
On November 9th, two ASBM Steering Committee members participated in the 2022 Generics and Biosimilars Conference (GRx+Biosims), held in Bethesda, MD. Andrew Spiegel of the Global Colon Cancer Association and Gavin Clingham of the Alliance for Patient Access both shared patient perspectives on biosimilars at a panel entitled “The Patient Voice in Drug Development”. The purpose […]
